TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock News
NYSE:TAK - New York Stock Exchange, Inc. - US8740602052 - ADR - Currency: USD
TAK Latest News, Press Relases and Analysis
Build 2025 Highlights Microsoft (MSFT)’s Push Toward a Collaborative AI Future
We recently published a list of 11 AI Stocks On Wall Street’s Radar. In this article, we are going to take a look at where Microsoft Corporation (NASDAQ:MSFT) stands against other AI stocks on Wall Street’s radar. US President Donald Trump is all set to revive the country’s struggling coal industry. Last month, he signed […]
Vertiv Enhances AI Infrastructure with NVIDIA (NVDA) 800V DC
We recently published a list of 15 AI Stocks Surging on News and Analyst Ratings. In this article, we are going to take a look at where Vertiv Holdings Co (NYSE:VRT) stands against other AI stocks that are surging on news and analyst ratings. According to an analysis by global management consulting firm McKinsey & […]
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
Top 4 GARP Stocks With Attractive PEG Ratios to Watch
Here we present four high-growth GARP picks based on discounted PEG. These are PAK, FIVN, LTM and MFG.
US and China to slash tariffs for 90 days as Trump and Xi likely to talk 'maybe at the end of the week'
US and China agreed to a 90-day pause on their trade war following high-stakes talks this past weekend in Switzerland.
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025. We recommend the stock to prospective investors.
Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs
Takeda reported a 25% drop in FY2024 net profit but saw revenue and operating profit growth.
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress
Best Value Stocks to Buy for April 30th
SKM, TAK and PHIN made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 30, 2025.
Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?
Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.
Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice
Does Takeda Pharmaceutical Co. (TAK) have what it takes to be a top stock pick for momentum investors? Let's find out.
New Strong Buy Stocks for April 30th
DB, SPOT, SONY, CIVB and TAK have been added to the Zacks Rank #1 (Strong Buy) List on April 30, 2025.
TAK vs. DSNKY: Which Stock Is the Better Value Option?
TAK vs. DSNKY: Which Stock Is the Better Value Option?
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
TAK vs. DSNKY: Which Stock Is the Better Value Option?
Why Ambev SA (ABEV) is Surging in 2025
We recently published a list of Why These 15 Consumer Defensive Stocks Are Surging in 2025. In this article, we are going to take a look at where Ambev SA (NYSE:ABEV) stands against other consumer defensive stocks that are surging in 2025. The stock market has taken a sharp turn after two years of blockbuster […]
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
Mentions: PTGX
La Agencia Europea de Medicamentos aprueba una opción adicional de administración subcutánea de TAKHZYRO®
La Agencia Europea de Medicamentos (EMA) ha aprobado una opción adicional de administración subcutánea de TAKHZYRO® (lanadelumab) para pacientes de 12 años o...
Die Europäische Arzneimittelagentur (EMA) hat eine zusätzliche Option zur subkutanen Verabreichung von TAKHZYRO® (Lanadelumab) für Patienten ab 12 Jahren mit wiederkehrenden Attacken des hereditären Angioödems (HAE) genehmigt
/PRNewswire/ -- Takeda (TSE:4502/NYSE:TAK) gab heute bekannt, dass die EMA eine zusätzliche 2-ml-Fertigpen-Option für TAKHZYRO® (Lanadelumab) zur subkutanen...
L'Agence européenne des médicaments (EMA) a approuvé une option supplémentaire d'administration sous-cutanée pour TAKHZYRO® (lanadelumab) chez les patients âgés de 12 ans et plus souffrant d'attaques récurrentes d'angio-œdème héréditaire (AOH).
/PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) annonce aujourd'hui que l'EMA a approuvé une option supplémentaire de stylo prérempli de 2 ml pour TAKHZYRO®...
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
/PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab)...
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
